Systemic Lupus Erythematosus (SLE) Clinical Trials

Find Systemic Lupus Erythematosus (SLE) Clinical Trials Near You

A Phase IIa, Open-Label, Single-Arm Study With an Initial Safety Run-In and Dose Expansion of ICG318 (BCMA-CD19-IL-15/IL15sushi cCAR T) in Participants With Refractory Systemic Lupus Erythematosus, With or Without Lupus Nephritis

Status: Recruiting
Location: See all (4) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This Phase IIa, open-label, single-arm study includes an initial Safety Run-In followed by dose expansion to evaluate the safety, tolerability, cellular kinetics, pharmacodynamics, and preliminary clinical activity of a single infusion of ICG318 in participants with refractory SLE, with or without LN. Participants will receive protocol-specified lymphodepletion followed by ICG318 at the recommended Phase 2 dose.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 16
Maximum Age: 70
Healthy Volunteers: f
View:

• Age 16-70 years at the time of signing the informed consent

• Have a diagnosis of SLE by EULAR/ACR 2019 criteria for ≥6 months.

• Have at least one of an antinuclear antibody, anti-double-stranded deoxyribonucleic acid (dsDNA), or elevated anti-Smith (Sm) antibody

• Inadequate response to 2 prior standard of care therapies, used for at least three months

• SLE Disease Activity Index 2000 (SLEDAI-2K) score of ≥7 at Screening

• For LN cohort participants. Kidney biopsy result within 6 months prior to Screening indicating Class III or IV (alone or in combination with Class V).

Locations
United States
Illinois
University of Chicago
NOT_YET_RECRUITING
Chicago
New York
New York Medical College
NOT_YET_RECRUITING
Hawthorne
NorthWell
RECRUITING
New Hyde Park
Pennsylvania
Fox Chase Cancer Center- Temple BMT
NOT_YET_RECRUITING
Philadelphia
Contact Information
Primary
Adam Chowdhury, MD, MBA
Adam.Chowdhury@icellgene.com
2404238999
Time Frame
Start Date: 2026-09
Estimated Completion Date: 2028-12
Participants
Target number of participants: 20
Treatments
Experimental: Single arm
Biologic drug infusion
Sponsors
Leads: iCell Gene Therapeutics

This content was sourced from clinicaltrials.gov

Similar Clinical Trials